- Company
- Imfinzi builds evidence for biliary tract cancer reimb
- by Whang, byung-woo Oct 2, 2024 05:49am
- AstraZeneca is reattempting to extend reimbursement of its immuno-oncology drug imfinzi (durvalumab) after announcing significant clinical outcomes in biliary tract cancer. Amid the rising interest in Imfinzi’s reimbursement reapplication review, with patient petitions being posted on the National Assembly's e-petition website, the outcome
- Company
- Will the Imfinzi·Imjudo combo be reimb within the year?
- by Eo, Yun-Ho Oct 2, 2024 05:49am
- Whether the combination of the immuno-oncology drugs Imfinzi and Imjudo will be reimbursed for liver cancer in Korea is gaining attention. In June, AstraZeneca Korea submitted an application for the reimbursement of the PD-L1 inhibitor Imfinzi (durvalumab) and CTLA-4 inhibitor Imjudo (tremelimumab) combination for liver cancer. There
- Company
- "Expanded scope for the newborn screening test"
- by Whang, byung-woo Oct 2, 2024 05:48am
- "Conducting genetic testing on family members and related families when a baby is found to be a carrier from a newborn screening test can identify more individuals with carriers. For rare diseases, such as Gaucher's disease, early diagnosis improves the patient's quality of life and saves the societal cost." Starting this year, the items for
- Company
- Jardiance generics prepare for final launch in Korea
- by Kim, Jin-Gu Sep 30, 2024 05:47am
- Generic companies are in the midst of last-minute preparations to enter the market for the SGLT inhibitor diabetes drug Jardiance (empagliflozin), which is set to expire in just about half a year. With Forxiga’s market withdrawal expected to leave an annual sales gap of KRW 50 billion, the race to fill this gap is expected to intensify among
- Company
- New myelodysplastic syndrome drug 'Reblozyl' lands Big 5 DC
- by Eo, Yun-Ho Sep 30, 2024 05:46am
- The treatment for myelodysplastic syndrome (MDS), 'Reblozyl,' is available for prescription at tertiary general hospitals. Sources said that Bristol Myers Squibb (BMS) Pharmaceutical Korea's Reblozyl (luspatercept) has passed all drug committees (DC) of the 'Big 5' medical centers, including Samsung Medical Center, Seoul National Univers
- Company
- Phesgo can be prescribed in Korea with reimbursement
- by Eo, Yun-Ho Sep 30, 2024 05:46am
- Breast cancer biobetter ‘Phesgo’ can now be prescribed in general hospitals in Korea with insurance reimbursement. According to industry sources, Phesgo (pertuzumab/trastuzumab), which is a subcutaneous injection combination of Roche's Perjeta and Herceptin, has passed drug committees (DC) reviews of tertiary hospitals in Korea, includi
- Company
- K-Phama companies are targeting Southeast Asia
- by Heo, sung-kyu Sep 27, 2024 05:53am
- Korean pharmaceutical companies target Indonesia to establish a bridgehead for Southeast Asia market entry. Companies have invested in Indonesia by buidling manufacturing plants. The government and associations are also in support. According to pharmaceutical companies on September 20th, pharmaceutical companies, the government, and or
- Company
- 'Treatment options for psoriasis are evolving'
- by Son, Hyung Min Sep 27, 2024 05:53am
- “In the field of psoriasis, the development of many biologics has been largely abandoned due to the lack of convincing data showing similar efficacy to marketed drugs. On the other hand, in the field of oral drugs, interest in the TYK2 mechanism has increased upon the introduction of Sotyktu, increasing the industry’s R&D on such oral dr
- Company
- KRPIA expresses concerns over drug approval fee hike
- by Eo, Yun-Ho Sep 27, 2024 05:53am
- “The pharmaceutical industry is bound to feel burdened by the sudden decision. We hope that the new drug approval system will be adjusted through discussions with the industry.” The Korean Research-based Pharmaceutical Industry Association (KRPIA) expressed the pharmaceutical industry's stance regarding the amendment to the 'Fee Regulat
- Company
- Switching between JAKis for RA yet to be reimbursed
- by Eo, Yun-Ho Sep 27, 2024 05:52am
- The plan to allow insurance reimbursement when switching between JAK inhibitors in rheumatoid arthritis, which was expected to take effect in October, has been postponed. According to Dailypharm coverage, the health authorities have recently put on hold the notification of the proposed revision that allows switching between JAK inhibitors
